MetLife Investment Management’s Astria Therapeutics ATXS Stock Holding History

MetLife Investment Management’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,743	Closed	-$298K	–	2771
2025 Q4	$298K	Buy	22,743 +4,377	+24%	+$52.3K	﹤0.01%	2073
2025 Q3	$134K	Sell	18,366 -6,587	-26%	-$44.6K	﹤0.01%	2520
2025 Q2	$134K	Buy	24,953 +1,604	+7%	+$7.78K	﹤0.01%	2393
2025 Q1	$125K	Sell	23,349 -3,656	-14%	-$25.6K	﹤0.01%	2419
2024 Q4	$241K	Hold	27,005	–	–	﹤0.01%	2205
2024 Q3	$297K	Hold	27,005	–	–	﹤0.01%	2068
2024 Q2	$246K	Buy	27,005 +1,342	+5%	+$13.1K	﹤0.01%	2121
2024 Q1	$361K	Buy	25,663 +12,090	+89%	+$151K	﹤0.01%	1854
2023 Q4	$104K	Hold	13,573	–	–	﹤0.01%	2593
2023 Q3	$101K	Hold	13,573	–	–	﹤0.01%	2569
2023 Q2	$113K	Buy	+13,573	New	+$157K	﹤0.01%	2603

MetLife Investment Management's ATXS Position: Q1 2026 in Review

MetLife Investment Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 22,743 shares — an estimated $298K sold.

MetLife Investment Management first reported a position in ATXS in Q2 2023 and held it in 11 quarters. The position peaked at $361K in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

MetLife Investment Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
MetLife Investment Management sold 22,743 Astria Therapeutics shares in Q1 2026, an estimated $298K.
MetLife Investment Management first reported a position in Astria Therapeutics in Q2 2023 and held it in 11 quarters.
MetLife Investment Management's Astria Therapeutics position peaked at $361K in Q1 2024.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.